• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

周期蛋白依赖性激酶合成致死性在 DNA 损伤反应中的作用。

Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response.

机构信息

Department of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.

Doctoral School of Exact and Natural Sciences, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.

出版信息

Int J Mol Sci. 2022 Mar 24;23(7):3555. doi: 10.3390/ijms23073555.

DOI:10.3390/ijms23073555
PMID:35408915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8998982/
Abstract

Cyclin-dependent kinases (CDKs) are pivotal mediators and effectors of the DNA damage response (DDR) that regulate both the pathway components and proteins involved in repair processes. Synthetic lethality (SL) describes a situation in which two genes are linked in such a way that the lack of functioning of just one maintains cell viability, while depletion of both triggers cell death. Synthetic lethal interactions involving CDKs are now emerging, and this can be used to selectively target tumor cells with DNA repair defects. In this review, SL interactions of CDKs with protooncogene products MYC, poly (ADP-ribose) polymerase (PARP-1), and cellular tumor antigen p53 (TP53) are discussed. The individual roles of each of the SL partners in DDR are described.

摘要

细胞周期蛋白依赖性激酶(CDKs)是 DNA 损伤反应(DDR)的关键介质和效应物,调节参与修复过程的途径成分和蛋白质。合成致死性(SL)描述了这样一种情况,即两个基因以这样的方式联系在一起,以至于仅仅缺乏一个基因的功能就能维持细胞活力,而耗尽两个基因则会引发细胞死亡。现在已经出现了涉及 CDKs 的合成致死相互作用,这可以用于选择性地靶向具有 DNA 修复缺陷的肿瘤细胞。在这篇综述中,讨论了 CDK 与原癌基因产物 MYC、多聚(ADP-核糖)聚合酶(PARP-1)和细胞肿瘤抗原 p53(TP53)的 SL 相互作用。描述了每个 SL 伙伴在 DDR 中的单独作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/d4c7ba9f03db/ijms-23-03555-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/4d347a7b674c/ijms-23-03555-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/d4dd1413ceac/ijms-23-03555-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/d4c7ba9f03db/ijms-23-03555-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/4d347a7b674c/ijms-23-03555-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/d4dd1413ceac/ijms-23-03555-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78cb/8998982/d4c7ba9f03db/ijms-23-03555-g003.jpg

相似文献

1
Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response.周期蛋白依赖性激酶合成致死性在 DNA 损伤反应中的作用。
Int J Mol Sci. 2022 Mar 24;23(7):3555. doi: 10.3390/ijms23073555.
2
Evolving DNA repair synthetic lethality targets in cancer.在癌症中不断发展的 DNA 修复合成致死靶标。
Biosci Rep. 2022 Dec 22;42(12). doi: 10.1042/BSR20221713.
3
Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.合成致死策略:超越胰腺癌中的BRCA1/2突变
Cancer Sci. 2020 Sep;111(9):3111-3121. doi: 10.1111/cas.14565. Epub 2020 Aug 6.
4
Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells.Rho 激酶(ROCK)抑制剂在 BRCA2 缺陷细胞中诱导多种有丝分裂缺陷和合成致死。
Elife. 2023 Apr 19;12:e80254. doi: 10.7554/eLife.80254.
5
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.聚(ADP-核糖)聚合酶抑制增强了 DNA 损伤剂诱导的 p53 依赖性和非依赖性 DNA 损伤反应。
Cell Cycle. 2011 Dec 1;10(23):4074-82. doi: 10.4161/cc.10.23.18170.
6
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.Rad51降解:在胶质母细胞瘤溶瘤病毒-聚(ADP-核糖)聚合酶抑制剂联合治疗中的作用
J Natl Cancer Inst. 2017 Mar 1;109(3):1-13. doi: 10.1093/jnci/djw229.
7
The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation.细胞周期蛋白依赖性激酶 5 耗竭对多聚(ADP-核糖)聚合酶活性和辐射反应的影响。
Cell Mol Life Sci. 2012 Mar;69(6):951-62. doi: 10.1007/s00018-011-0811-6. Epub 2011 Sep 16.
8
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.聚腺苷二磷酸核糖聚合酶抑制剂与 MYC 阻断联合应用的合成致死性不依赖于三阴性乳腺癌的 BRCA 状态。
Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.
9
DNA damage response pathways in tumor suppression and cancer treatment.肿瘤抑制与癌症治疗中的DNA损伤反应途径。
World J Surg. 2009 Apr;33(4):661-6. doi: 10.1007/s00268-008-9840-1.
10
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.DNA损伤修复与聚(ADP-核糖)聚合酶抑制在癌症治疗中的新作用
Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.

引用本文的文献

1
Integrated multi-omics analysis identifies SELENOP and PKMYT1 as immune-metabolic hub genes in breast cancer.综合多组学分析确定硒蛋白P和M期周期蛋白依赖性蛋白激酶1为乳腺癌中的免疫代谢枢纽基因。
Biochem Biophys Rep. 2025 Aug 6;43:102198. doi: 10.1016/j.bbrep.2025.102198. eCollection 2025 Sep.
2
Multifaced Anticancer Potential of Doxorubicin: Spotlight on Breast Cancer.多柔比星的多面抗癌潜力:聚焦乳腺癌
Dis Res. 2025 Mar;5(1):19-36. doi: 10.54457/dr.202402015. Epub 2025 Jan 17.
3
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.

本文引用的文献

1
Cyclin-dependent kinases in DNA damage response.细胞周期蛋白依赖性激酶在 DNA 损伤反应中的作用。
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188716. doi: 10.1016/j.bbcan.2022.188716. Epub 2022 Mar 7.
2
Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment.细胞周期蛋白依赖性激酶抑制剂及其在结直肠癌治疗中的治疗潜力。
Front Pharmacol. 2021 Dec 21;12:757120. doi: 10.3389/fphar.2021.757120. eCollection 2021.
3
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials.
联合使用聚(ADP-核糖)聚合酶(PARP)抑制剂治疗BRCA野生型癌症的策略
Front Oncol. 2024 Aug 2;14:1441222. doi: 10.3389/fonc.2024.1441222. eCollection 2024.
4
An Integrated Molecular Networking and Docking Approach to Characterize the Metabolome of and Its Pharmaceutical Potentials.一种用于表征[具体对象]代谢组及其药物潜力的综合分子网络和对接方法。 (注:原文中“of and Its Pharmaceutical Potentials”部分缺少具体内容)
Metabolites. 2023 Oct 23;13(10):1104. doi: 10.3390/metabo13101104.
5
Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.多柔比星——一种具有多种抗癌活性机制的药物。
Cells. 2023 Feb 19;12(4):659. doi: 10.3390/cells12040659.
6
Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.高级别浆液性卵巢癌中扩增的治疗靶点——文献综述及定量评估。
Cancer Gene Ther. 2023 Jul;30(7):955-963. doi: 10.1038/s41417-023-00589-z. Epub 2023 Feb 20.
7
Repurposing benzbromarone as antifolate to develop novel antifungal therapy for Candida albicans.将苯溴马隆重新用作抗叶酸剂,开发新型抗白念珠菌真菌感染疗法。
J Mol Model. 2022 Jun 18;28(7):193. doi: 10.1007/s00894-022-05185-w.
细胞周期蛋白依赖性激酶(CDK)抑制剂在实体瘤中的研究进展:临床试验综述。
Clin Transl Oncol. 2022 Feb;24(2):161-192. doi: 10.1007/s12094-021-02688-5. Epub 2021 Aug 7.
4
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges.用细胞周期蛋白依赖性激酶抑制剂进行抗癌治疗:影响和挑战。
Expert Rev Mol Med. 2021 Jun 9;23:e6. doi: 10.1017/erm.2021.3.
5
CDK inhibitors in cancer therapy, an overview of recent development.癌症治疗中的细胞周期蛋白依赖性激酶(CDK)抑制剂——近期进展综述
Am J Cancer Res. 2021 May 15;11(5):1913-1935. eCollection 2021.
6
Targeting CDK9 for Anti-Cancer Therapeutics.靶向CDK9用于抗癌治疗。
Cancers (Basel). 2021 May 1;13(9):2181. doi: 10.3390/cancers13092181.
7
Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer.细胞周期蛋白依赖性激酶抑制剂(CDKIs)与 DNA 损伤反应:信号通路与癌症之间的联系。
DNA Repair (Amst). 2021 Jun;102:103103. doi: 10.1016/j.dnarep.2021.103103. Epub 2021 Mar 26.
8
Targeting "undruggable" c-Myc protein by synthetic lethality.通过合成致死作用靶向“不可成药”的 c-Myc 蛋白。
Front Med. 2021 Aug;15(4):541-550. doi: 10.1007/s11684-020-0780-y. Epub 2021 Mar 4.
9
The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction.实体癌中DNA修复、端粒稳态与p53突变状态的相互作用:风险、预后及预测
Cancers (Basel). 2021 Jan 27;13(3):479. doi: 10.3390/cancers13030479.
10
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.利用 MYC 的合成致死性在数字时代治疗癌症。
Trends Pharmacol Sci. 2021 Mar;42(3):166-182. doi: 10.1016/j.tips.2020.11.014. Epub 2021 Jan 6.